ELTX Stock Forecast: Elicio Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$1.45
−3.33% on the day

The median 12-month analyst price target for Elicio Therapeutics, Inc. is $10. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 51 of 100 as at 21 Nov 2026 — in the upper half.

Market cap
$41.0M
Ticker Nerd rank
51/ 100
Median analyst target
$10
Analysts covering
3
Revenue$0.0
Operating income−$10.4M
Net income−$8.2M
Free cash flow−$8.2M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−3.3%
1M
−7.6%
YTD
−81.8%
1Y
−81.9%
From 52W high
−90.2%
From 52W low
+3.6%
$1
$15
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Elicio Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
51/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
81
Revisions
75
Volatility
64
Issuance
46
Value
39
Momentum
28
Accruals
27
Quality
23

Growth (81): Sales and profits are climbing, and climbing faster than before.

Quality (23): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

ELTX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ELTX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$5$10$15$20Jan 26Apr 26Jul 26Oct 26ELTXHigh $21Median $10Low $8

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says3 analysts
2
Buy
1
Hold
0
Sell
$8
Low
$10
Median
$21
High
Recent analyst actionsNewest first

Of the 20 most recent actions, 1 moved their price target up and 2 moved it down.

DateFirmActionRatingTarget
10 Nov 2026HC Wainwright & Co.MaintainsBuy$23 → $21
24 Sept 2026B. Riley SecuritiesMaintainsBuy$27 → $8.00
18 Aug 2026HC Wainwright & Co.ReiteratesBuy$23
18 June 2026Ladenburg ThalmannAssumesBuy$12
16 June 2026Jones TradingDowngradeHold—
15 June 2026HC Wainwright & Co.MaintainsBuy$17 → $23
10 June 2026B. Riley SecuritiesInitiatesBuy—
28 May 2026HC Wainwright & Co.ReiteratesBuy—
15 Apr 2026Ladenburg ThalmannInitiatesBuy—
13 Mar 2026HC Wainwright & Co.MaintainsBuy—
10 Mar 2026Rodman & RenshawInitiatesBuy—
17 July 2025HC Wainwright & Co.MaintainsBuy—
2 Apr 2025HC Wainwright & Co.ReiteratesBuy—
31 Oct 2024Jones TradingInitiatesBuy—
23 Aug 2024HC Wainwright & Co.ReiteratesBuy—
6 June 2024HC Wainwright & Co.ReiteratesBuy—
22 May 2024HC Wainwright & Co.ReiteratesBuy—
1 May 2024HC Wainwright & Co.MaintainsBuy—
1 Apr 2024OppenheimerReiteratesPerform—
17 Jan 2024HC Wainwright & Co.MaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for ELTX.

Market Radar

This page is one stock. Monday covers all of them.

ELTX appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

ELTX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Elicio Therapeutics, Inc. returned −81.9% against +6.9% for the S&P 500, dividends included.

ELTX vs S&P 500, last 12 monthsTotal return, rebased to 100
050100150Jan 26Apr 26Jul 26Oct 26ELTXS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ELTX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
0
Analysts cutting
0
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
—
Price / book
2.2×

Cheaper than 41% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
—
Returns & dividend
Return on equity
−315.3%

Higher than 5% of US stocks

Return on assets
−70.6%

Higher than 5% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Elicio Therapeutics, Inc. has a market value of $41.0M and an enterprise value of $24.1M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$37.8M.

  • Free cash flow in the twelve months to 30 June 2026: −$37.7M.

  • Shares outstanding: 21.9M.

  • Elicio Therapeutics, Inc. employs 33 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 21 Nov 2026

Data provided by Twelve Data

Peers

ELTX and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
ELTXElicio Therapeutics, Inc.$41.0M51
BMEABiomea Fusion, Inc.$41.7M46
OSTXOS Therapies, Inc.$42.0M23
INKTMiNK Therapeutics, Inc.$39.8M62
CRBPCorbus Pharmaceuticals Holdings, Inc.$42.4M12
DWTXDogwood Therapeutics, Inc.$39.6M71
ELOXEloxx Pharmaceuticals, Inc.$43.1M18

Take a look at ELTX’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Elicio Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about ELTX

What is the ELTX stock price forecast for 2026-2027?

The median 12-month analyst price target for Elicio Therapeutics, Inc. is $10, with estimates ranging from $8 to $21. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ELTX stock a buy right now?

Of the 3 analysts covering Elicio Therapeutics, Inc., 2 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Elicio Therapeutics, Inc. 51 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ELTX?

As at 21 Nov 2026, Elicio Therapeutics, Inc. ranks 51 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Growth (81 of 100).

Will ELTX stock go up?

No one can know that. What the data says: the median 12-month target from 3 analysts is $10, and Ticker Nerd's factor model ranks Elicio Therapeutics, Inc. 51 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ELTX stock forecast for 2030?

No analyst covering Elicio Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ELTX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $8 to $21 over the next 12 months.

How has ELTX stock performed over the past year?

Elicio Therapeutics, Inc. returned -81.9% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Elicio Therapeutics, Inc. do?

Elicio Therapeutics Inc. is a clinical-stage biotechnology company focused on developing lymph node-targeted immunotherapies for cancer. The company’s current pipeline centers on its Amphiphile (AMP) platform, which is designed to deliver vaccines, immunomodulators, and adjuvants to the lymph nodes to support a stronger immune response.

Company

About Elicio Therapeutics, Inc.

Elicio Therapeutics Inc. is a clinical-stage biotechnology company focused on developing lymph node-targeted immunotherapies for cancer. The company’s current pipeline centers on its Amphiphile (AMP) platform, which is designed to deliver vaccines, immunomodulators, and adjuvants to the lymph nodes to support a stronger immune response. Its programs include investigational therapies for KRAS-driven cancers, BRAF-driven cancers, and other mutation-defined tumor types, alongside broader efforts in cancer immunotherapy and selected infectious disease applications. Elicio Therapeutics Inc. works at the intersection of oncology and immune system engineering, using platform-based drug design to create both personalized and off-the-shelf candidates for clinically important targets. Headquartered in Boston, Massachusetts, Elicio Therapeutics Inc. is positioned as a specialized player in the biotechnology market with a focus on hard-to-treat cancers and precision immunotherapy approaches.

CEO Mr. Robert T. Connelly · 33 employees · United States · https://elicio.com